Abbott advances pulsed field ablation clinical studies and launches new technology to support advanced cardiac mapping

Enrollment completed ahead of schedule in the global ide for abbott's volt™ pfa system global focalflex trial now underway for abbott's tactiflex™ duo ablation catheter, sensor enabled™ advisor™ hd grid x mapping catheter, sensor enabled™, receives u.s. food and drug administration clearance, begins commercial launch abbott park, ill., oct. 10, 2024 /prnewswire/ -- abbott (nyse: abt) announced today it has achieved new major milestones to support the company's growing suite of pulsed field ablation (pfa) solutions in electrophysiology: early completion of enrollment in the volt-af ide study supporting the volt™ pfa system, and the launch of the focalflex trial to assess the company's tactiflex™ duo ablation catheter, sensor enabled™ (se), which will be used in the treatment of patients with paroxysmal atrial fibrillation.
ABT Ratings Summary
ABT Quant Ranking